证券代码：300016 证券简称：北陆药业 债券代码：123082 债券简称：北陆转债 2025 年 7 月 11 日投资者关系活动记录表 编号：【2025】第 021 号 投资者关系 活动类别 √特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 参与单位名称 及人员姓名 国联基金：刘柏川 首创证券：王斌 时 间 2025 年 7 月 11 日 地 点 公司会议室 上市公司接 待人员姓名 董事会秘书：邵泽慧 投资者关系活动 主要内容介绍 Q1、公司对比剂产品战略布局情况 近年来，公司多项对比剂产品已陆续被纳入国家药品集中采购，对 比剂行业原有的竞争格局和销售模式发生了巨大的变化，为市场参与者 带来压力的同时，也带来了发展的机遇。经过近两年的积极调整，公司 已逐步克服了碘对比剂主打产品管线受集采价格下降带来的巨大挑战， 逐渐出现回暖趋势，对比剂产品销售额稳步保持增长。 2024 年度，公司积极完成碘海醇注射液、碘帕醇注射液、碘克沙 醇注射液的集采执标、接续等工作，努力扩大各产品的市场份额。 公司钆类对比剂产品更加丰富，随着钆特酸葡胺注射液于 2024 年 获批， ...

Group 1 - The core issue revolves around the geopolitical struggle for rare earth resources, with the US, Japan, India, and Australia forming an alliance to counter China's dominance through the "Critical Minerals Initiative" [1][2] - The alliance's strategy involves Japan providing rare earth patent technology, Australia supplying high-quality rare earth minerals, India managing hazardous waste, and the US benefiting from this division of labor to break China's monopoly [2][4] - China's response includes the implementation of a new Mineral Resources Law that categorizes rare earths as strategic minerals and introduces export controls on certain rare earth elements, leveraging its significant global market share [4][5] Group 2 - The alliance faces critical weaknesses, including reliance on outdated technology, an imbalance in raw material availability, and China's control over essential equipment for rare earth processing, which could cripple the alliance if export controls are enacted [5][7] - The strategic implications extend beyond economics, as the US defense industry heavily relies on Chinese rare earths for military applications, highlighting the risks associated with supply chain vulnerabilities [7][9] - Experts predict that the alliance will struggle to achieve significant progress in the short term due to technological barriers and China's ongoing advancements in the rare earth industry, indicating a prolonged and escalating resource conflict [9]

Group 1 - The core issue is the dependency of the U.S. automotive and military industries on Chinese rare earth elements, particularly high-power magnets, which has led to production halts in companies like Ford [1][3] - Rare earth elements, once considered cheap, are now critical for advanced technologies, with significant quantities required for products like Tesla vehicles and military aircraft [3][4] - China's recent export controls on key rare earth elements have exposed vulnerabilities in the U.S. supply chain, with military stockpiles only sufficient for 18 months and a projected $300 billion needed to rebuild the supply chain over a decade [4][6] Group 2 - The U.S. has rare earth mines but lacks the refining capacity for critical heavy rare earths, forcing reliance on China for processing [6][8] - The geopolitical struggle over rare earths has led to secret agreements between the U.S. and China, revealing the limitations of Western efforts to reduce dependence on Chinese supplies [6][10] - China controls 70% of global rare earth supply and 95% of refining technology, giving it significant leverage in the global market [8][10] Group 3 - The value chain of rare earths shows that raw materials are worth significantly less than processed products, highlighting the economic importance of refining and manufacturing capabilities [8][10] - The price of Chinese rare earth permanent magnets has surged by 40% in the past year, indicating a shift in market dynamics and the realization of their true value [8]

据新华社报道，根据《中华人民共和国出口管制法》等有关法律法规，4月4日，商务部会同海关总署发布关于对钐、钆、铽、镝、镥、钪、钇等7 类中重稀土相关物项实施出口管制措施的公告，并于发布之日起正式实施。此举引发多国关注。 商务部新闻发言人在公告发布当日表示，此次中国政府依法对相关物项实施出口管制，目的是更好维护国家安全和利益，履行防扩散等国际义 务。相关物项具有军民两用属性，对其实施出口管制是国际通行做法。 美日印澳"四方安全对话"（QUAD）7月1日在美国华盛顿召开外长会议，美国当天宣布与日印澳启动关键矿产倡议。 当地时间2025年7月1日，美国华盛顿特区，日本外务大臣岩屋毅在美国国务院与印太"四方安全对话"机制成员国举行记者会。视觉中国 图 据环球网报道，美国国务院发言人布鲁斯6月30日表示，"四方安全对话"外长会议将重申美日印澳对自由开放的"印太地区"的共同承诺，并突出四 国战略伙伴"维护主权、加强海上安全和建立弹性供应链"的共同决心。 据美国广播公司（ABC）报道，美日印澳四国外长在华盛顿会谈后发表联合声明，宣布启动"四方关键矿产倡议"，旨在确保关键矿产供应链的安 全与多元化，加强经济安全和集体韧性。路透 ...

一、你真的了解稀土吗？7种稀土元素的高价值密码 中国自2025年4月精准实施对七种稀土元素的出口管制，这些元素分别是：钐、钆、铽、镝、镥、钪、钇——它们是全球高端制造业的重要"命门"。这些稀 土元素在国防和科技领域具有无可替代的战略价值，其中： 4. "高纯镥"：用于核反应堆中的中子探测，而"钪铝合金"则显著减轻了导弹结构的重量，提升其机动性和射程。 美国国防部的报告已明确承认，其军工产业链的"92%稀土依赖进口"，其中超过70%来自中国。如果失去这些稀土元素，连美军最先进的武器也可能迅速陷 入技术瓶颈，成为过时装备。 1. "钐钴磁体"：用于爱国者导弹的雷达行波管和制导系统，确保微波信号的精准聚焦和导弹的高效导航。 2. "铽镝合金"：大幅提升F-35战机发动机的耐高温性能，每架战机的发动机中含有417公斤的此合金。 3. "钇钆石榴石"：是相控阵雷达中移相器的核心材料，直接影响雷达的探测精度和范围。 二、贸易战中的中国"稀土王牌"令美国焦虑 美国战略与国际问题研究中心的报告坦言，美国目前并不具备完全独立提炼所有重稀土的能力。重稀土元素是F-35战斗机等尖端军工装备的核心材料，而随 着全球化红利的消退，西方 ...

Group 1 - The company participated in a centralized procurement program in Xinjiang, aiming to select its gadobutrol injection and gadopentetate dimeglumine injection [1] - The proposed price for gadopentetate dimeglumine injection (15ml:7.04g) is 80.26 yuan per unit, while gadobutrol injection (15ml:7.935g) is priced at 185.69 yuan per unit [1] - For the year 2024, the sales revenue from gadopentetate dimeglumine injection is projected to be 236 million yuan, accounting for 24.01% of the company's total revenue for the period [1]

证券代码：300016 证券简称：北陆药业 债券代码：123082 债券简称：北陆转债 2025 年 6 月 6 日投资者关系活动记录表 编号：【2025】第 018 号 投资者关系 活动类别 √特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 参与单位名称 及人员姓名 天风证券 周海涛 民生加银基金 郝梦娇 时 间 2025 年 6 月 6 日 地 点 线上 上市公司接 待人员姓名 董事会秘书：邵泽慧 投资者关系活动 主要内容介绍 Q1、公司对比剂产品战略布局情况 近年来，公司多项对比剂产品已陆续被纳入国家药品集中采购， 对比剂行业原有的竞争格局和销售模式发生了巨大的变化，为市场参 与者带来压力的同时，也带来了发展的机遇。经过近两年的积极调整， 公司已逐步克服了碘对比剂主打产品管线受集采价格下降带来的巨大 挑战，逐渐出现回暖趋势。 报告期内，公司积极完成碘海醇注射液、碘帕醇注射液、碘克沙 醇注射液的集采执标、接续等工作，努力扩大各产品的市场份额。 公司钆类对比剂产品更加丰富，随着钆特酸葡胺注射液于 2024 年获批，公司已拥有包括钆喷酸葡胺注射液、钆贝葡胺注 ...

日前，北方稀土（600111）举办2025年第一季度业绩说明会。公司高管介绍，通过深化营销模式创新， 强化营销运作，报告期内主要产品销量同比增长，公司稀土产品价格掌控力和市场影响力进一步提升。 今年一季度，公司实现营业收入92.87亿元，同比增长约六成；归属于上市公司股东的净利润4.31亿元， 同比增长727.3%；扣非后净利润4.3亿元，同比增长11622.98%。 受上游原料供应增量放缓及下游消费刺激等政策影响，稀土市场整体活跃度好于上年同期，以稀土镨钕 产品为代表的主要稀土产品价格呈现上涨态势，成交较好。 在稀土出口方面，北方稀土高管介绍，目前轻稀土出口许可证正常办理，正常出口；中重稀土两用物项 出口许可证已提交内蒙古自治区商务厅审批。公司主要出口产品为镨钕、镧铈、氧化钆、氧化铽、氧化 钇等，主要出口到日本、美国、德国等地，预计今年的出口量与去年的出口水平相当。另外，公司产品 出口收入占总收入的比重很小。 从战略地位来看，公司高管介绍，随着世界科技革命和产业变革的加速演进，稀土元素的应用范围正在 进一步拓展，具有与其它产业强大的耦合能力，预计"双碳"战略的实施，新能源、新材料等领域将持续 高速发展，风力 ...

Core Viewpoint - The company expects its export volume this year to be comparable to last year's level, with ongoing projects in green smelting upgrades set to commence in the second half of 2025 [1] Export Performance - The company is currently processing export licenses for light rare earths normally, while the export licenses for medium and heavy rare earths have been submitted for approval [1] - Major export products include praseodymium-neodymium, lanthanum-cerium, gadolinium oxide, terbium oxide, and yttrium oxide, primarily exported to Japan, the United States, and Germany [1] - Export revenue constitutes a small proportion of the company's total income [1] Green Smelting Project - The green smelting upgrade and transformation project is the largest and most complete rare earth smelting and separation project globally [1] - The first phase of the project has entered full production, while the second phase is planned to start construction in the second half of 2025 [1]

Group 1 - The company is established as a joint-stock company in accordance with the Company Law and other relevant regulations [2][3] - The registered capital of the company is RMB 491,855,896 [3] - The company was approved by the China Securities Regulatory Commission to issue 17 million shares of ordinary stock to the public in 2009 [2][3] Group 2 - The company's business scope includes the production and sale of large-volume injections, small-volume injections, tablets, granules, and raw materials [4][5] - The company aims to leverage its technological advantages and high-tech talent resources to provide high-quality pharmaceutical products and services [4] Group 3 - The company has a share structure consisting of ordinary shares, with a total of 491,855,896 shares issued [8] - The shares are issued at a par value of RMB 1 per share [8] Group 4 - The company’s shareholders have the right to receive dividends and participate in decision-making processes at the shareholders' meetings [12][13] - Shareholders holding more than 5% of the shares are subject to specific trading restrictions [10][11] Group 5 - The company’s board of directors is responsible for major decisions, and shareholders have the right to request the convening of shareholder meetings under certain conditions [20][23] - The company must disclose information regarding significant transactions and decisions to ensure transparency [42][43]